Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model

Antiviral Research

Volumn 155, Issue , 2018, Pages 89-96

  Li, H S ^a   Kuok, Denise I T ^a   Cheung, M C ^a   Ng, Mandy M T ^a   Ng, K C ^a   Hui, Kenrie P Y ^a   Peiris, J S Malik ^a   Chan, Michael C W ^a   Nicholls, John M ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cyclosporine; Ex vivo explants; Middle East Respiratory Syndrome Coronavirus (MERS CoV); Type I interferon

Indexed keywords

ALPHA INTERFERON; CYCLOSPORINE; ANTIVIRUS AGENT;

ANIMAL CELL; ARTICLE; BRONCHUS; COMBINATION DRUG THERAPY; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MONOTHERAPY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VERO CELL LINE; VIRUS CULTURE; VIRUS REPLICATION; CELL CULTURE TECHNIQUE; DNA REPLICATION; DRUG EFFECT; PHYSIOLOGY; RESPIRATORY SYSTEM; VIROLOGY;

ANTIVIRAL AGENTS; BRONCHI; CELL CULTURE TECHNIQUES; CYCLOSPORINE; DNA REPLICATION; HUMANS; INTERFERON-ALPHA; LUNG; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; RESPIRATORY SYSTEM; VIRUS REPLICATION;

EID: 85047058929     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2018.05.007     Document Type: Article

References (24)

1. Al-Tawfiq, J.A., Memish, Z.A., Update on therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV). Expert Rev. Anti Infect. Ther. 15:3 (2017), 269–275, 10.1080/14787210.2017.1271712.
2. Al-Tawfiq, J.A., Momattin, H., Dib, J., Memish, Z.A., Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int. J. Infect. Dis. 20 (2014), 42–46, 10.1016/j.ijid.2013.12.003.
3. Arabi, Y.M., Balkhy, H.H., Hayden, F.G., Bouchama, A., Luke, T., Baillie, J.K., et al. Middle East respiratory syndrome. N. Engl. J. Med. 376:6 (2017), 584–594, 10.1056/NEJMsr1408795.
4. Chan, R.W., Chan, M.C., Agnihothram, S., Chan, L.L., Kuok, D.I., Fong, J.H., et al. Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J. Virol. 87:12 (2013), 6604–6614, 10.1128/JVI.00009-13.
5. Chan, R.W., Hemida, M.G., Kayali, G., Chu, D.K., Poon, L.L., Alnaeem, A., et al. Tropism and replication of Middle East respiratory syndrome coronavirus from dromedary camels in the human respiratory tract: an in-vitro and ex-vivo study. Lancet Respir. Med. 2:10 (2014), 813–822, 10.1016/S2213-2600(14)70158-4.
6. de Groot, R.J., Baker, S.C., Baric, R.S., Brown, C.S., Drosten, C., Enjuanes, L., et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J. Virol. 87:14 (2013), 7790–7792, 10.1128/JVI.01244-13.
7. de Wilde, A.H., Falzarano, D., Zevenhoven-Dobbe, J.C., Beugeling, C., Fett, C., Martellaro, C., et al. Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model. Virus Res. 228 (2017), 7–13, 10.1016/j.virusres.2016.11.011.
8. de Wilde, A.H., Raj, V.S., Oudshoorn, D., Bestebroer, T.M., van Nieuwkoop, S., Limpens, R.W., et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment. J. Gen. Virol. 94:Pt 8 (2013), 1749–1760, 10.1099/vir.0.052910-0.
9. Falzarano, D., de Wit, E., Rasmussen, A.L., Feldmann, F., Okumura, A., Scott, D.P., et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat. Med. 19:10 (2013), 1313–1317, 10.1038/nm.3362.
10. Henry, S.D., Metselaar, H.J., Lonsdale, R.C.B., Kok, A., Haagmans, B.L., Tilanus, H.W., van der Laan, L.J.W., Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin a and interferon-α. Gastroenterology 131:5 (2006), 1452–1462, 10.1053/j.gastro.2006.08.027.
11. Hui, K.P.Y., Chan, L.L.Y., Kuok, D.I.T., Mok, C.K.P., Yang, Z.-F., Li, R.-F., et al. Tropism and innate host responses of influenza A/H5N6 virus: an analysis of ex vivo and in vitro cultures of the human respiratory tract. Eur. Respir. J., 49(3), 2017, 10.1183/13993003.01710-2016.
12. Inoue, K., Sekiyama, K., Yamada, M., Watanabe, T., Yasuda, H., Yoshiba, M., Combined Interferon Alpha2b and Cyclosporin A in the Treatment of Chronic Hepatitis C: Controlled Trial, vol. 38, 2003.
13. Ivashkiv, L.B., Donlin, L.T., Regulation of type I interferon responses. Nat. Rev. Immunol. 14:1 (2014), 36–49, 10.1038/nri3581.
14. Kaur, S., Sassano, A., Dolniak, B., Joshi, S., Majchrzak-Kita, B., Baker, D.P., et al. Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc. Natl. Acad. Sci. U. S. A. 105:12 (2008), 4808–4813, 10.1073/pnas.0710907105.
15. Korean Society of Infectious, D., Korean Society for Healthcare-associated Infection, C., & Prevention, The same Middle East respiratory syndrome-coronavirus (MERS-CoV) yet different outbreak patterns and public health impacts on the far East expert opinion from the rapid response team of the Republic of Korea. Infect. Chemother. 47:4 (2015), 247–251, 10.3947/ic.2015.47.4.247.
16. Kroczynska, B., Kaur, S., Platanias, L.C., Growth suppressive cytokines and the AKT/mTOR pathway. Cytokine 48:1–2 (2009), 138–143, 10.1016/j.cyto.2009.07.009.
17. Lim, Y., Ng, Y., Tam, J., Liu, D., Human coronaviruses: a review of virus–host interactions. Diseases, 4(3), 2016, 26.
18. Liu, J.P., Ye, L., Wang, X., Li, J.L., Ho, W.Z., Cyclosporin A inhibits hepatitis C virus replication and restores interferon-alpha expression in hepatocytes. Transpl. Infect. Dis. Offic. J. Transplant. Soc. 13:1 (2011), 24–32, 10.1111/j.1399-3062.2010.00556.x.
19. Omrani, A.S., Saad, M.M., Baig, K., Bahloul, A., Abdul-Matin, M., Alaidaroos, A.Y., et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect. Dis. 14:11 (2014), 1090–1095, 10.1016/S1473-3099(14)70920-X.
20. Perlman, S., McCray, P.B. Jr., Person-to-person spread of the MERS coronavirus–an evolving picture. N. Engl. J. Med. 369:5 (2013), 466–467, 10.1056/NEJMe1308724.
21. Platanias, L.C., Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5:5 (2005), 375–386, 10.1038/nri1604.
22. Saleiro, D., Mehrotra, S., Kroczynska, B., Beauchamp, E.M., Lisowski, P., Majchrzak-Kita, B., et al. Central role of ULK1 in type I interferon signaling. Cell Rep. 11:4 (2015), 605–617, 10.1016/j.celrep.2015.03.056.
23. Shen, Z., He, H., Wu, Y., Li, J., Cyclosporin a inhibits rotavirus replication and restores interferon-beta signaling pathway in vitro and in vivo. Plos One, 8(8), 2013, e71815, 10.1371/journal.pone.0071815.
24. Zaki, A.M., van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D., Fouchier, R.A., Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367:19 (2012), 1814–1820, 10.1056/NEJMoa1211721.